The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
Abstract
Purpose: The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIα gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients. Patients and Methods: In the Danish Breast Cancer Cooperative Group trial 89D, 980 pre- and postmenopausal primary patients were randomly allocated to either CMF (cyclophosphamide, methotrexate, and fluorouracil; n = 500) or CEF (cyclophosphamide, epirubicin, and fluorouracil; n = 480) times 9, between January 1990 and November 1999. Tumor tissue was retrospectively identified from 805 patients and was analyzed for HER2-positivity and for TOP2A-amplifications and deletions. Results: HER2-positivity was found in 33% of the 805 investigated tumors and was not a predictive marker for epirubicin sensitivity. TOP2A changes were identified in 23% of the 773 investigated tumors: 12% had TOP2A amplifications and 11% had TOP2A deletions. We found that patients with TOP2A amplification had an increased recurrence-free (RFS; hazard ratio [HR], 0.43; 95% CI, 0.24 to 0.78) and overall survival (OS; HR, 0.57; 95% CI, 0.29 to 1.13), respectively if treated with CEF compared with CMF, and that patients with TOP2A deletions had an almost identical hazard ratio (RFS: HR, 0.63; 95% CI, 0.36 to 1.11; OS: HR, 0.56; 95% CI, 0.30 to 1.04). This is in contrast to patients with a normal TOP2A genotype for whom similar outcome was observed in both treatment arms (RFS: HR, 0.90; 95% CI, 0.70 to 1.17; OS: HR, 0.88; 95% CI, 0.66 to 1.17). Conclusion: TOP2A amplification—and possibly deletion—seems to be predictive markers for the effect of adjuvant epirubicin containing therapy in primary breast cancer, but a final conclusion has to await a confirmative study or a meta-analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1346 · Cited by 612
Järvinen, T. A. H., Tanner, M., Rantanen, V., Bärlund, M., Borg, Å., Grénman, S., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64952-8 · Cited by 387
Paik, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.1991 · Cited by 304
Yamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Leo, A. D., Gancberg, D., Larsimont, D., Tanner, M., Järvinen, T. A. H., Rouas, G., Dolci, S., Leroy, J.-Y., Paesmans, M., Isola, J. J., et al. (2002) · PubMed · Cited by 267
Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J.-F., Borel, C., Mors, R., Haegelé, P., Eber, M., & Ghnassia, J.-P. (2004) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00675-0 · Cited by 264
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner, M., Järvinen, P., & Isola, J. J. (2001) · PubMed · Cited by 215
Coon, J. S., Marcus, E., Gupta-Burt, S., SEELIG, S. A., Jacobson, K., Chen, S., RENTA, V., Fronda, G., & Preisler, H. D. (2002) · PubMed · Cited by 193
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen, T. A. H., Tanner, M., Barlund, M. T., Borg, Å., & Isola, J. J. (1999) · PubMed · Cited by 188
DNA topoisomerase I and II as targets for rational design of new anticancer drugs
Cummings, J., & Smyth, J. F. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058584 · Cited by 134
Park, K., Kim, J., Lim, S., & Han, S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00745-1 · Cited by 113
Leo, A. D., Larsimont, D., Gancberg, D., Järvinen, T. A. H., Beauduin, M., Vindevoghel, A., Michel, J., Focan, C., Ries, F., Gobert, P., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011669223035 · Cited by 107
HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer
Moliterni, A., Ménard, S., Valagussa, P., Biganzoli, E. M., Boracchi, P., Balsari, A., Casalini, P., Tomasic, G., Marubini, E., Pilotti, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.021 · Cited by 99
Cardoso, F., Durbecq, V., Larsimont, D., Paesmans, M., Leroy, J., Rouas, G., Sotiriou, C. P., Renard, N., Richard, V., Piccart, M. J., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.1.201 · Cited by 94
Withoff, S., Keith, W. N., Knol, A., Coutts, J., Hoare, S. F., Mulder, N., & de Vries, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.393 · Cited by 79
Olsen, K. E., Knudsen, H., Rasmussen, B., Balslev, E., Knoop, A. S., Ejlertsen, B., Nielsen, K. V., Schönau, A., Overgaard, J., & for the Danish Breast Cancer Co-operative Group (2004) · Acta Oncologica · doi:10.1080/02841860310019007 · Cited by 73
Self-citation
Cited by
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., & Overgaard, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5565 · Cited by 568
Self-citationHER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
Metadata
- Authors
- Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdóttir, K., Olsen, K. E., Mouridsen, H., & Ejlertsen, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-20
- Volume
- 23
- Issue
- 30
- Pages
- 7483-7490
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096471659
- Cited by
- 320
- References
- 21
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.